ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pemetrexed

Also written as “pemetrexed”, “ALIMTA” and “Pemetrexed/Cisplatin”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Ovarian Neoplasms · Colorectal Neoplasms, led by 9 companies.

Drug pagePemetrexed: every studyMany companies study it; this page follows only the 108 they lead. All 434 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 22, 2006108 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly940 open or runningphase 4since Sep 22, 2006Apr 29, 2002none ahead
Hoffmann-La Rocheits history only72 open or runningphase 3since Aug 18, 2009Aug 18, 2009Jun 30, 2027phase 3 · NCT05112965
Betta Pharmaceuticalsits history only10 open or runningphase 4since Mar 31, 2014Mar 31, 2014none ahead
Hikma Pharmaceuticalsits history only10 open or runningphase 4since Feb 26, 2018Feb 26, 2018none ahead
Johnson & Johnsonits history only11 open or runningphase 3since Aug 31, 2020Aug 31, 2020none ahead
NovoCureits history only10 open or runningphase 2since Mar 19, 2015Mar 19, 2015none ahead
Polaris Groupits history only10 open or runningphase 3since Mar 5, 2016Mar 5, 2016none ahead
Shanghai Miracogenits history only11 open or runningphase 3since Feb 22, 2023Feb 22, 2023none ahead
Takedaits history only10 open or runningphase 2since Jun 22, 2006Jun 22, 2006none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Parexel, Daiichi Sankyo, Arcus Biosciences, Ono Pharmaceutical and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Sep 12, 2005.

  1. May 28, 2008Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00686959 · 598 enrolled · United States, Argentina, Australia and more
  2. Sep 26, 2008Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00762034 · 939 enrolled · United States
  3. Nov 10, 2008Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00789373 · 939 enrolled · Australia, Belgium, Finland and more
  4. Mar 20, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00867009 · 113 enrolled · Austria, Germany, Greece and more
  5. Apr 23, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00887549 · 70 enrolled · Ireland, United Kingdom
  6. Jul 28, 2009Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00948675 · 361 enrolled · United States
  7. Oct 21, 20092 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT01000480, NCT01004250
  8. Oct 29, 2009Phase 3 study in Carcinoma, Non-Small-Cell LungNCT01005680 · 256 enrolled · China
  9. Nov 19, 2009Phase 3 study in Carcinoma, Non-Small-Cell LungNCT01017874 · 236 enrolled · Hong Kong, Korea, Republic of, Singapore and more
  10. Nov 24, 2009Phase 4 study in Carcinoma, Non-Small-Cell LungNCT01020786 · 109 enrolled · Japan
  11. Jan 20, 2010Phase 2 study in Head and Neck NeoplasmsNCT01057589 · 66 enrolled · Belgium, France, Germany and more
  12. Mar 15, 2010Phase 2 study in Head and Neck NeoplasmsNCT01087970 · 69 enrolled · United States
  13. Jul 8, 20102 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT01160744, NCT01165021
  14. Nov 2, 20112 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT01473563, NCT01469000

TargetBeta

“Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 94 Eli Lilly leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT01469000Carcinoma, Non-Small-Cell Lung · China, Japan, Korea, Republic of and more2CompletedApr 2015195
NCT01473563Carcinoma, Non-Small-Cell Lung · Sweden, United Kingdom2CompletedSep 201352
NCT01165021Carcinoma, Non-Small-Cell Lung · Italy2CompletedJul 201319
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedJan 2014280
NCT01087970Head and Neck Neoplasms · United States2CompletedAug 201369
NCT01057589Head and Neck Neoplasms · Belgium, France, Germany and more2CompletedFeb 201266
NCT01020786Carcinoma, Non-Small-Cell Lung · Japan4CompletedMar 2011109
NCT01017874Carcinoma, Non-Small-Cell Lung · Hong Kong, Korea, Republic of, Singapore and more3CompletedApr 2013236
NCT01005680Carcinoma, Non-Small-Cell Lung · China3CompletedNov 2012256
NCT01004250Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Italy and more2CompletedNov 2012109
NCT01000480Carcinoma, Non-Small-Cell Lung · France, Germany, Italy and more2CompletedJan 201390
NCT00948675Carcinoma, Non-Small-Cell Lung · United States3CompletedJan 31, 2013361
NCT00887549Carcinoma, Non-Small-Cell Lung · Ireland, United Kingdom2CompletedJul 201070
NCT00867009Carcinoma, Non-Small-Cell Lung · Austria, Germany, Greece and more2CompletedMay 2011113
NCT00789373Carcinoma, Non-Small-Cell Lung · Australia, Belgium, Finland and more3CompletedJun 2010939
NCT00762034Carcinoma, Non-Small-Cell Lung · United States3CompletedApr 2012939
NCT00686959Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedOct 2014598
NCT00606021Carcinoma, Non-Small-Cell Lung · Egypt, Lebanon, Saudi Arabia2CompletedDec 2010106
NCT00550173Carcinoma, Non-Small-Cell Lung · Brazil, China, Hong Kong and more2CompletedJan 2012247
NCT00529100Carcinoma, Non-Small-Cell Lung · Canada2CompletedAug 201049
NCT00523419Osteosarcoma · France, Germany, Italy and more2CompletedJun 200932
NCT00520936Osteosarcoma · United States2CompletedFeb 201072
NCT00520676Carcinoma, Non-Small-Cell Lung · Australia, Brazil, China and more3CompletedJul 2010260
NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more2TerminatedOct 20084
NCT00490373Pancreatic Neoplasms · Germany2Completed52
NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom2Completed91
NCT00489359Ovarian Neoplasms · Argentina, Canada, Germany and more2CompletedFeb 201086
NCT00475657Small Cell Lung Carcinoma · Spain2TerminatedApr 20085
NCT00461786Ovarian Neoplasms · United States2CompletedOct 200751
NCT00447421Small Cell Lung Carcinoma · Belgium, Netherlands2TerminatedMay 20089
NCT00447057Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. · Austria, Germany, Hungary and more2CompletedJul 2010204
NCT00415194Head and Neck Neoplasms · United States, Argentina, Belgium and more3CompletedMar 2010795
NCT00415168Stomach Neoplasms · Russian Federation2CompletedJul 200953
NCT00409006Carcinoma, Non-Small-Cell Lung · China, Korea, Republic of, Taiwan2CompletedAug 200970
NCT00391274Carcinoma, Non-Small-Cell Lung · China3CompletedDec 2008211
NCT00386815Mesothelioma, Malignant · Japan2Completed20
NCT00383331Carcinoma, Non-Small-Cell Lung · United States2TerminatedJan 200819
NCT00380718Carcinoma, Non-Small-Cell Lung · Taiwan4CompletedSep 200833
NCT00377520Neoplasms · United States2CompletedOct 200727
NCT00374868Urologic Neoplasms · Spain2CompletedApr 200859
NCT00370292Carcinoma, Non-Small-Cell Lung · Italy2CompletedSep 200819
NCT00363415Small Cell Lung Carcinoma · United States, Argentina, Australia and more3CompletedJun 2008908
NCT00356525Lung Neoplasms · United States, Brazil, India2TerminatedJun 200841
NCT00350792Carcinoma, Non-Small-Cell Lung · France2CompletedNov 200862
NCT00330915Rectal Neoplasms · Sweden2CompletedJun 200837
NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more2CompletedApr 2010135
NCT00320515Stomach Neoplasms · Argentina, Mexico, South Korea and more2CompletedJul 200889
NCT00316225Carcinoma, Non-Small-Cell Lung · Denmark, Germany, Spain2CompletedMar 200931
NCT00308750Carcinoma, Non-Small-Cell Lung · United States2CompletedJul 2009218
NCT00259285Carcinoma, Non-Small-Cell Lung · Spain2TerminatedDec 200710
NCT00251550Malignant Pleural Mesotherioma · Japan2Completed12
NCT00192088Advanced Gastric Carcinoma · Italy2Completed43
NCT00191984Colorectal Neoplasms · France2CompletedFeb 200746
NCT00191750Carcinoma, Small Cell · United States2Completed80
NCT00191503Adenocarcinoma · Canada2Completed30
NCT00191412Liver Neoplasms · United States2Completed41
NCT00191347Breast Neoplasms · Canada2Completed30
NCT00191308Carcinoma, Non-Small-Cell Lung · Poland2CompletedJul 200830
NCT00191191Carcinoma, Non-Small-Cell Lung · Japan2CompletedOct 2008226
NCT00190983Uterine Cervical Dysplasia · United States2CompletedOct 200729

How it is read

Names in the registry

  • “Pemetrexed”, 74 entries
  • “pemetrexed”, 51 entries
  • “ALIMTA”, 7 entries
  • “Pemetrexed/Cisplatin”, 2 entries
  • “Pemetrexed/Carboplatin”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.